Physician profile
Mark Troiano
NPI 1962636696
$2,045.37
in general payments reported to CMS, 2019-2025
14 companies · $77.80 in 2025
The $77.80 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $291 · 2021: $328 · 2022: $191 · 2023: $245 · 2024: $19.36 · 2025: $77.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.02 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $453.25 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $389.31 | 2021-2025 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $311.56 | 2019-2023 | Andexxa |
| Boston Scientific Corporation | $306.52 | 2019-2025 | Watchman Flx, Patientcare Link |
| Abiomed | $214.38 | 2020-2023 | Impella |
| Janssen Pharmaceuticals, INC | $143.28 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.69 | 2019 | |
| Amgen INC. | $28.58 | 2019 | |
| Chiesi USA, INC. | $28.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.72 | 2019 | |
| Amarin Pharma, INC. | $13.78 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Troiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.